FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
This Quarter Return
+22.47%
1 Year Return
-6.87%
3 Year Return
+443.49%
5 Year Return
+535.97%
10 Year Return
–
AUM
$363M
AUM Growth
+$363M
(+19%)
Cap. Flow
+$34.9M
Cap. Flow
% of AUM
9.63%
Top 10 Holdings %
Top 10 Hldgs %
84.78%
Holding
30
New
4
Increased
7
Reduced
6
Closed
10
Top Buys
| 1 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
$12.6M |
| 2 |
AKAO
Achaogen, Inc.
AKAO
|
$10.6M |
| 3 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$9.66M |
| 4 |
Ascendis Pharma
ASND
|
$9.52M |
| 5 |
ALDR
Alder Biopharmaceuticals, Inc.
ALDR
|
$9.37M |
Top Sells
| 1 |
FibroGen
FGEN
|
$8.08M |
| 2 |
LOXO
Loxo Oncology, Inc
LOXO
|
$5.76M |
| 3 |
Forte Biosciences
FBRX
|
$5.73M |
| 4 |
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
|
$5.29M |
| 5 |
DERM
Dermira, Inc.
DERM
|
$3.6M |
Sector Composition
| 1 | Healthcare | 49.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AERI
1
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $94.8M | 26.11% | 1,950,477 | – | – |
|
|
ALDR
2
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $36M | 9.93% | 2,942,203 +765,000 | +35% | +$9.37M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $33.3M | 9.16% | 2,379,367 +438,517 | +23% | +$6.13M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $32.6M | 8.97% | 467,682 +7,682 | +2% | +$535K |
|
|
AKAO
5
DELISTED
Achaogen, Inc.
AKAO
| $30.5M | 8.4% | 1,912,106 +662,106 | +53% | +$10.6M |
|
|
AIMT
6
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $22.6M | 6.23% | 912,001 | – | – |
|
7
Wave Life Sciences
WVE
$1.53B
| $18.8M | 5.17% | 863,327 -140,773 | -14% | -$3.06M |
|
|
EPZM
8
DELISTED
Epizyme, Inc
EPZM
| $16.2M | 4.46% | 849,693 +50,330 | +6% | +$959K |
|
|
MYOK
9
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $12.6M | 3.48% | +295,000 | New | +$12.6M |
|
|
XLRN
10
DELISTED
Acceleron Pharma Inc.
XLRN
| $10.4M | 2.87% | 278,753 +258,867 | +1,302% | +$9.66M |
|
|
11
Ascendis Pharma
ASND
$11.8B
| $10.3M | 2.85% | 285,143 +262,743 | +1,173% | +$9.52M |
|
|
VRNA
12
Verona Pharma
VRNA
$9.16B
| $9.35M | 2.57% | 608,851 -4,750 | -0.8% | -$72.9K |
|
13
Aclaris Therapeutics
ACRS
$209M
| $6.79M | 1.87% | +262,950 | New | +$6.79M |
|
14
Pacific Biosciences
PACB
$393M
| $6.04M | 1.66% | 1,150,000 -100,000 | -8% | -$525K |
|
|
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
| $4.84M | 1.33% | +600,000 | New | +$4.84M |
|
|
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
| $4.61M | 1.27% | 50,000 -62,500 | -56% | -$5.76M |
|
17
Madrigal Pharmaceuticals
MDGL
$9.76B
| $4.5M | 1.24% | +100,000 | New | +$4.5M |
|
18
argenx
ARGX
$43.6B
| $3.99M | 1.1% | 176,500 | – | – |
|
|
19
Forte Biosciences
FBRX
$137M
| $3.65M | 1.01% | 293,177 -459,823 | -61% | -$5.73M |
|
|
DERM
20
DELISTED
Dermira, Inc.
DERM
| $1.16M | 0.32% | 43,071 -133,140 | -76% | -$3.6M |
|
21
Abeona Therapeutics
ABEO
$350M
| – | – | -18,334 | Closed | -$117K |
|
22
Ardelyx
ARDX
$1.53B
| – | – | -37,500 | Closed | -$191K |
|
|
23
FibroGen
FGEN
$47.8M
| – | – | -250,000 | Closed | -$8.08M |
|
24
Larimar Therapeutics
LRMR
$310M
| – | – | -234,092 | Closed | -$822K |
|
25
Sangamo Therapeutics
SGMO
$157M
| – | – | -154,000 | Closed | -$1.36M |
|